KA/EN
Register
Medicines reference
Search
Search
Product

Oxtra

Favourites

Oxytetracycline · Fatro von Franken, Fatro S.p.A.

2 forms: solution. In force in Georgia: 2 of 2 (veterinary register).

Forms and doses2 of 2 in force in Georgia

The dose from the product's label, by species and weight. Check the label of the pack you use.

Choose species and weight; the matching row will be highlighted.
Form Species Dose Frequency Georgia
5%, Solution · Cat Cat 0.16–0.24 ml/kg
Label dose for dogs and cats: 1.6-2.4 ml per 10 kg a day (8-12 mg/kg at 50 mg/ml), into a muscle, for 3-5 days; a 4 kg cat gets 0.64-0.96 ml.
 · once daily, 3-5 days		 once daily, 3-5 days Georgia Yes, veterinary
In force until 30 Jun 2028
Veterinary (National Food Agency)
In the register: ოქსტრა
№ 000381
Verified on: 15 Oct 2026
5%, Solution · Dog Dog 0.16–0.24 ml/kg
Label dose for dogs and cats: 1.6-2.4 ml per 10 kg a day (8-12 mg/kg at 50 mg/ml), into a muscle, for 3-5 days. UK-authorised 10% oxytetracycline products use 10 mg/kg.
 · once daily, 3-5 days		 once daily, 3-5 days Georgia Yes, veterinary
In force until 30 Jun 2028
Veterinary (National Food Agency)
In the register: ოქსტრა
№ 000381
Verified on: 15 Oct 2026
Details: pack, label wording, sources, registration

Oxtra 5%, Solution

50 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label.
5.3/10
Weak evidence support
vetman assessment

Oxtra

5%, 50 mg/ml, solution for injection
Assessed clinical scopeDog · Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label. · Intramuscular
Care settingVeterinary clinic or supervised treatment setting able to confirm the diagnosis, calculate injection volume, use deep IM technique, divide larger volumes among sites and reassess clinical response within 48-72 hours
vetman score 5.3/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000381 · Verified on 15 Oct 2026

A usable labelled dog/cat injectable for selected susceptible bacterial infections, but not a broad empirical default. Its exact dose and composition are transparent and locally authorised, while modern exact-product outcome and pharmacovigilance evidence are limited. Confirm susceptibility where feasible, protect renal/hepatic and growing patients, use deep IM technique and reassess early rather than extending an ineffective course.

Regulatory and scientific credibility6.5/10

The exact 50 mg/ml veterinary presentation has a current Georgian authorisation (000381, valid to 2028-06-30) and an official manufacturer instruction identifying composition, route, dog/cat dose, duration and local-tolerance precautions. It is not currently authorised as this exact strength in the checked EU/EEA, GB or US registers, and no regulator-hosted exact-product dossier or modern independent pharmacovigilance series was located.

Clinical efficacy5.0/10

Oxytetracycline is an established tetracycline with relevant susceptible-organism activity, and the exact label provides a coherent 8-12 mg/kg once-daily IM regimen for 3-5 days. However, its broad syndrome list is not supported by indication-specific modern dog/cat outcome trials, resistance can materially narrow coverage, and no exact-product comparative clinical study was located; culture and current susceptibility should define use.

Safety and tolerability5.0/10

The product is species-labelled and contains lidocaine to reduce injection discomfort, but tetracycline-class hypersensitivity, dysbiosis, hepatic/renal risk, deposition in developing teeth and bone, photosensitivity and superinfection remain relevant. Deep IM administration can cause local irritation, tissue injury and slow absorption with hardening, particularly at higher canine volumes; exact-product dog/cat safety evidence is mainly the label rather than a quantified modern series.

Clinical practicality4.5/10

The ready-to-use solution avoids reconstitution and is dosed once daily, but 0.16-0.24 ml/kg creates a clinically meaningful injection volume, especially in larger dogs. Deep IM technique, daily clinic/supervised administration for 3-5 days, site rotation or volume splitting and response review add treatment burden; concentration must be distinguished from 100 mg/ml immediate and 200 mg/ml depot products.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • Verify the exact 50 mg/ml immediate-release presentation with lidocaine. Do not substitute the 100 mg/ml product volume or the 200 mg/ml long-acting depot: concentration, excipients, dose interval and species evidence differ.
  • Give by deep intramuscular injection only. The exact label reports slow absorption and hardening around the injection site at higher canine doses; divide larger volumes among sites, use aseptic technique and monitor for pain, swelling, tissue injury or abscessation.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • The exact dog/cat label supports 0.16-0.24 ml/kg IM once daily for 3-5 days. Calculate milligrams and millilitres independently, account for lidocaine exposure, and do not exceed the labelled concentration-specific range without a separately sourced protocol.
Assessment sources
  1. Oxtra 5% official instruction2017
  2. Oxtra GE register audit2026
  3. VMD SPC 20242024
  4. MSD tetracyclines2026
  5. EMA AMEG 20252025
  6. Oxtra LA EU UPD2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Cat Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label.
5.3/10
Weak evidence support
vetman assessment

Oxtra

5%, 50 mg/ml, solution for injection
Assessed clinical scopeCat · Culture- and susceptibility-directed treatment of bacterial infection caused by oxytetracycline-susceptible organisms; not empirical treatment of every syndrome listed in the broad legacy label. · Intramuscular
Care settingVeterinary clinic or supervised treatment setting able to confirm the diagnosis, calculate injection volume, use deep IM technique, divide larger volumes among sites and reassess clinical response within 48-72 hours
vetman score 5.3/10 Weak evidence support
Evidence confidence: Low Georgia: Yes, veterinary · № 000381 · Verified on 15 Oct 2026

A usable labelled dog/cat injectable for selected susceptible bacterial infections, but not a broad empirical default. Its exact dose and composition are transparent and locally authorised, while modern exact-product outcome and pharmacovigilance evidence are limited. Confirm susceptibility where feasible, protect renal/hepatic and growing patients, use deep IM technique and reassess early rather than extending an ineffective course.

Regulatory and scientific credibility6.5/10

The exact 50 mg/ml veterinary presentation has a current Georgian authorisation (000381, valid to 2028-06-30) and an official manufacturer instruction identifying composition, route, dog/cat dose, duration and local-tolerance precautions. It is not currently authorised as this exact strength in the checked EU/EEA, GB or US registers, and no regulator-hosted exact-product dossier or modern independent pharmacovigilance series was located.

Clinical efficacy5.0/10

Oxytetracycline is an established tetracycline with relevant susceptible-organism activity, and the exact label provides a coherent 8-12 mg/kg once-daily IM regimen for 3-5 days. However, its broad syndrome list is not supported by indication-specific modern dog/cat outcome trials, resistance can materially narrow coverage, and no exact-product comparative clinical study was located; culture and current susceptibility should define use.

Safety and tolerability5.0/10

The product is species-labelled and contains lidocaine to reduce injection discomfort, but tetracycline-class hypersensitivity, dysbiosis, hepatic/renal risk, deposition in developing teeth and bone, photosensitivity and superinfection remain relevant. Deep IM administration can cause local irritation, tissue injury and slow absorption with hardening, particularly at higher canine volumes; exact-product dog/cat safety evidence is mainly the label rather than a quantified modern series.

Clinical practicality4.5/10

The ready-to-use solution avoids reconstitution and is dosed once daily, but 0.16-0.24 ml/kg creates a clinically meaningful injection volume, especially in larger dogs. Deep IM technique, daily clinic/supervised administration for 3-5 days, site rotation or volume splitting and response review add treatment burden; concentration must be distinguished from 100 mg/ml immediate and 200 mg/ml depot products.

Full-course cost-effectiveness-

Price was not assessed and is excluded from the overall score.

Important safety and use flags

  • Use only for a diagnosed or strongly supported bacterial infection when oxytetracycline susceptibility is plausible; obtain culture and susceptibility whenever feasible. Do not continue an ineffective empirical course merely because the historical label lists many syndromes.
  • Verify the exact 50 mg/ml immediate-release presentation with lidocaine. Do not substitute the 100 mg/ml product volume or the 200 mg/ml long-acting depot: concentration, excipients, dose interval and species evidence differ.
  • Give by deep intramuscular injection only. The exact label reports slow absorption and hardening around the injection site at higher canine doses; divide larger volumes among sites, use aseptic technique and monitor for pain, swelling, tissue injury or abscessation.
  • Do not use with known hypersensitivity to oxytetracycline, another tetracycline or an excipient. Allergic or anaphylactic reactions are possible; stop treatment and provide emergency care for acute facial swelling, dyspnoea, collapse or other systemic reaction.
  • Avoid or use only after a documented benefit-risk decision in renal or hepatic impairment, dehydration, hypovolaemia or severe systemic illness. Tetracyclines can increase BUN and cause renal/hepatic toxicity; obtain baseline values and monitor clinically relevant change.
  • Tetracyclines deposit in developing teeth and bone. Avoid late pregnancy and use in growing/neonatal animals unless the expected benefit clearly outweighs tooth discolouration, enamel/bone effects and the unestablished exact-product reproductive risk.
  • Review concurrent antimicrobials. The applicable oxytetracycline labels advise against simultaneous bactericidal penicillins or cephalosporins; do not combine automatically, and let culture, infection site and a deliberate antimicrobial plan govern any exception.
  • Do not dilute or mix this product with calcium-containing solutions. Verify physical and chemical compatibility before any admixture; use a separate syringe and administration site when compatibility has not been established.
  • Monitor response within 48-72 hours and reassess diagnosis, source control and susceptibility if improvement is absent. Broad-spectrum exposure can select resistant bacteria and permit fungal, yeast or nonsusceptible bacterial superinfection.
  • The exact dog/cat label supports 0.16-0.24 ml/kg IM once daily for 3-5 days. Calculate milligrams and millilitres independently, account for lidocaine exposure, and do not exceed the labelled concentration-specific range without a separately sourced protocol.
Assessment sources
  1. Oxtra 5% official instruction2017
  2. Oxtra GE register audit2026
  3. VMD SPC 20242024
  4. MSD tetracyclines2026
  5. EMA AMEG 20252025
  6. Oxtra LA EU UPD2026
  7. Canine LA oxytetracycline PK2001
Assessed: 22 Oct 2026The overall score uses 25/25/25/15/10 weights. An unassessed price is excluded and the remaining weights are proportionally renormalised.
Composition / strength
Oxytetracycline50 mg/ml
Formulation Type
Solution
Administration route
Intramuscular
Manufacturer
Fatro von Franken · Argentina
Manufacturer (register)
FATRO S.p.A., Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 866, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
In force until 30 Jun 2028
Veterinary (National Food Agency)
In the register: ოქსტრა
№ 000381
Verified on: 15 Oct 2026
 EU No
Verified on: 15 Oct 2026
 UK No
Verified on: 15 Oct 2026
 US No
Verified on: 15 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
DoseSpeciesWeightRouteFrequencySource
0.16–0.24 ml/kg
Label dose for dogs and cats: 1.6-2.4 ml per 10 kg a day (8-12 mg/kg at 50 mg/ml), into a muscle, for 3-5 days; a 4 kg cat gets 0.64-0.96 ml.
 Cat Any weight Intramuscular once daily, 3-5 days
Oxtra 5% official instruction
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Oxtra 5% 50 mg/ml injectable veterinary solution - official product instruction
Fatro Fedagro official product information, 2017
0.16–0.24 ml/kg
Label dose for dogs and cats: 1.6-2.4 ml per 10 kg a day (8-12 mg/kg at 50 mg/ml), into a muscle, for 3-5 days. UK-authorised 10% oxytetracycline products use 10 mg/kg.
 Dog Any weight Intramuscular once daily, 3-5 days
Oxtra 5% official instruction
Manufacturer material
Information published by the maker or a seller, such as a datasheet or product page. A medicines regulator has not necessarily reviewed it.
Oxtra 5% 50 mg/ml injectable veterinary solution - official product instruction
Fatro Fedagro official product information, 2017
10%, Solution - No label dose in the reference yet - Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოქსტრა 10%
№ 1-03/45
Verified on: 23 Oct 2026
Details: pack, label wording, sources, registration

Oxtra 10%, Solution

100 mg/ml, solution for injection
vetman assessment
vetman’s 10-point assessment brings together a product’s regulatory credibility, clinical efficacy, safety and practicality. Cost-effectiveness is assessed only when reliable data are available. It is informational and does not replace a veterinarian’s clinical judgment for an individual patient.
Dog Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation
Not rateable
No numerical score assigned
vetman assessment

Oxtra

10%, 100 mg/ml, solution for injection
Assessed clinical scopeDog · Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation ·
Care settingVeterinarian-directed antimicrobial treatment only after exact Georgian label verification, diagnosis and susceptibility-led product selection
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, veterinary · № 1-03/45 · Verified on 23 Oct 2026
Not rateable

The Georgian register confirms Fatro Oxtra 10%, a 100 ml injectable solution whose composition cell prints oxytetracycline hydrochloride 100 mg without a denominator, and lists dogs as a target species. No exact public label establishes canine route, dose, indication details, excipients or safety. Oxtra DD and the Cyprus-authorised Oxtra 10% are different authorisation identities; old canine class PK and comparator labels cannot resolve that collision, so numerical axes would be invented.

The local registration and nominal product identity are real, but the catalogue currently merges clinical instructions from two different Fatro presentations. Until the Georgian authorised leaflet/SPC links exact formulation, route, regimen and safety to authorisation 1-03/45, publish no dog/cat dose and no numerical product score.

Important safety and use flags

  • No exact public Georgian clinical label was found. NFA verifies registration, strength, pack, manufacturer and target species but does not independently establish dog/cat route, dose, indication details or safety.
  • Do not transfer the Oxtra DD 10 mg/kg SC/IM regimen. Oxtra DD is a current, transparent Fatro comparator with a different trade and authorisation identity; matching manufacturer and nominal strength are not proof of formulation equivalence.
  • Do not transfer the EU Oxtra 10% regimen. Its 92.7 mg/ml oxytetracycline is explicitly equivalent to 100 mg/ml hydrochloride, but it is a separate authorisation for cattle, horses, pigs and sheep, not the Georgian dog/cat product.
  • No dog/cat dose is published here. Obtain the authorised Georgian package leaflet/SPC and link it to authorisation 1-03/45 before using this exact presentation.
  • Use an antimicrobial only for a diagnosed bacterial infection and base selection on pathogen identification and susceptibility where feasible. Broad legacy spectrum does not make oxytetracycline an empirical default.
  • Tetracycline hypersensitivity, hepatic or renal impairment, pregnancy and growth-phase tooth/bone effects are important class/comparator concerns; exact Georgian warnings and incidence remain unverified.
  • Injection-site irritation, tissue injury, photosensitivity, delayed healing and hypersensitivity are plausible comparator risks. Route, volume, repeat-site handling and local tolerance cannot be assumed for this exact product.
  • Until the exact Georgian instruction is obtained, do not mix, dilute or combine this product with another injectable at one site; those restrictions are established for the comparator, while this formulation’s compatibility is unverified.
  • Concurrent penicillins or cephalosporins and polyvalent-cation products require exact-label review. The Oxtra DD interaction text is a comparator warning, not proof that every formulation has identical compatibility.
  • Current exact Georgian price/availability and a defensible dog/cat regimen are both unavailable, so full-course cost and vial waste are not assessed.
Assessment sources
  1. Oxtra 10% GE register2026
  2. Oxtra DD VMD product record2025
  3. Oxtra DD VMD label2025
  4. Oxtra DD EU UPD2026
  5. Oxtra 10% 92.7 EU UPD2026
  6. EMA AMEG 20252025
  7. MSD tetracyclines2026
  8. Canine oxytetracycline PK1978
  9. Canine oxytetracycline PBPK2015
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Cat Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation
Not rateable
No numerical score assigned
vetman assessment

Oxtra

10%, 100 mg/ml, solution for injection
Assessed clinical scopeCat · Potential treatment of a confirmed oxytetracycline-susceptible bacterial infection using the exact Georgian Oxtra 10% presentation ·
Care settingVeterinarian-directed antimicrobial treatment only after exact Georgian label verification, diagnosis and susceptibility-led product selection
vetman score Not rateable No numerical score assigned
Evidence confidence: Low Georgia: Yes, veterinary · № 1-03/45 · Verified on 23 Oct 2026
Not rateable

The Georgian register confirms Fatro Oxtra 10%, a 100 ml injectable solution whose composition cell prints oxytetracycline hydrochloride 100 mg without a denominator, and lists cats as a target species. No exact public label establishes feline route, dose, indication details, excipients or safety. Oxtra DD is a different authorisation identity, and the feline observational cohort did not identify this product; numerical axes would therefore be invented.

The local registration and nominal product identity are real, but the catalogue currently merges clinical instructions from two different Fatro presentations. Until the Georgian authorised leaflet/SPC links exact formulation, route, regimen and safety to authorisation 1-03/45, publish no dog/cat dose and no numerical product score.

Important safety and use flags

  • No exact public Georgian clinical label was found. NFA verifies registration, strength, pack, manufacturer and target species but does not independently establish dog/cat route, dose, indication details or safety.
  • Do not transfer the Oxtra DD 10 mg/kg SC/IM regimen. Oxtra DD is a current, transparent Fatro comparator with a different trade and authorisation identity; matching manufacturer and nominal strength are not proof of formulation equivalence.
  • Do not transfer the EU Oxtra 10% regimen. Its 92.7 mg/ml oxytetracycline is explicitly equivalent to 100 mg/ml hydrochloride, but it is a separate authorisation for cattle, horses, pigs and sheep, not the Georgian dog/cat product.
  • No dog/cat dose is published here. Obtain the authorised Georgian package leaflet/SPC and link it to authorisation 1-03/45 before using this exact presentation.
  • Use an antimicrobial only for a diagnosed bacterial infection and base selection on pathogen identification and susceptibility where feasible. Broad legacy spectrum does not make oxytetracycline an empirical default.
  • Tetracycline hypersensitivity, hepatic or renal impairment, pregnancy and growth-phase tooth/bone effects are important class/comparator concerns; exact Georgian warnings and incidence remain unverified.
  • Injection-site irritation, tissue injury, photosensitivity, delayed healing and hypersensitivity are plausible comparator risks. Route, volume, repeat-site handling and local tolerance cannot be assumed for this exact product.
  • Until the exact Georgian instruction is obtained, do not mix, dilute or combine this product with another injectable at one site; those restrictions are established for the comparator, while this formulation’s compatibility is unverified.
  • Concurrent penicillins or cephalosporins and polyvalent-cation products require exact-label review. The Oxtra DD interaction text is a comparator warning, not proof that every formulation has identical compatibility.
  • Current exact Georgian price/availability and a defensible dog/cat regimen are both unavailable, so full-course cost and vial waste are not assessed.
Assessment sources
  1. Oxtra 10% GE register2026
  2. Oxtra DD VMD product record2025
  3. Oxtra DD VMD label2025
  4. Oxtra DD EU UPD2026
  5. Oxtra 10% 92.7 EU UPD2026
  6. EMA AMEG 20252025
  7. MSD tetracyclines2026
  8. Feline Mycoplasma treatment cohort2021
Assessed: 23 Oct 2026No axis or overall score is shown when the available evidence does not support a responsible numerical assessment.
Composition / strength
Oxytetracycline100 mg/ml
Formulation Type
Solution
Manufacturer
Fatro S.p.A. · Italy
Manufacturer (register)
FATRO S.p.A. Ltd, Italy
Manufacturer and country as in the veterinary medicines register (National Food Agency), row 37, 19 Oct 2026.
Source: NFA veterinary medicines register ↗
Registration
Georgia Yes, veterinary
Veterinary (National Food Agency)
In the register: ოქსტრა 10%
№ 1-03/45
Verified on: 23 Oct 2026
 EU Not confirmed
Verified on: 23 Oct 2026
 UK Not confirmed
Verified on: 23 Oct 2026
 US Not confirmed
Verified on: 23 Oct 2026
Controlled in Georgia
No
Checked against the narcotics law, Annex 1, lists I-IV, and Order No. 22/n.
Verified on: 16 Oct 2026
Information not fully verified No dog/cat dose or administration route is published for this exact Georgian presentation. Do not transfer the Oxtra DD 10 mg/kg SC/IM regimen, the EU Oxtra 10% 92.7 mg/ml food-animal regimen, the Oxtra 5% dose or a long-acting formulation. Obtain the authorised Georgian package leaflet/SPC before clinical use.

Oxytetracycline: No dose supported by a publicly verifiable source yet

Known Contraindications

  • Critical
    Do not use oxytetracycline in patients with hypersensitivity to oxytetracycline or another tetracycline.
  • Critical
    Oxytetracycline crosses the placenta and is not recommended in late pregnancy. Tetracycline deposition can discolor developing teeth, cause enamel hypoplasia and reduced mineralisation, and delay fetal skeletal development. If no alternative exists, use only after a benefit-risk assessment.
  • Warning
    Avoid oxytetracycline in young growing animals because it is deposited in developing teeth and bones and can cause yellow, brown, or grey discoloration and impaired mineralisation.
  • Warning (Dog)
    Do not administer this oxytetracycline formulation intravenously to dogs. Use only a route authorised for the selected product.
  • Warning (Cat)
    Do not administer this oxytetracycline formulation intravenously to cats. Use only a route authorised for the selected product.
  • Caution
    Use oxytetracycline cautiously in hepatic impairment. Hepatic toxicity is a rare adverse effect, and dose reduction may be necessary.
  • Caution
    Use oxytetracycline cautiously in renal impairment; dose reduction may be necessary.

Known Drug Interactions

  • Major warning Oxytetracycline + Benzathine Benzylpenicillin
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Oxytetracycline + Ceftriaxone
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Amoxicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Ampicillin + Oxytetracycline
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Major warning Oxytetracycline + Procaine Benzylpenicillin
    Do not give oxytetracycline at the same time as bactericidal antimicrobials such as penicillins or cephalosporins because their antibacterial effects may be antagonistic.
    Recommendation: Do not administer concurrently.
  • Minor warning Oxytetracycline + Calcium Carbonate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
  • Minor warning Oxytetracycline + Calcium chloride
    Do not mix oxytetracycline with calcium-containing infusion solutions because they are physically incompatible.
    Recommendation: Do not mix oxytetracycline with lactated Ringer solution or run them through the same line.
  • Minor warning Oxytetracycline + Magnesium Carbonate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.
  • Minor warning Oxytetracycline + Sucralfate
    Divalent and trivalent cations, including magnesium, iron, aluminium, and calcium, can chelate oxytetracycline and reduce its absorption. Do not give it at the same time as milk or antacids.
    Recommendation: Separate this medicine from oral oxytetracycline in time.

Products are connected by name, active ingredients, or therapeutic group. They are not direct substitutes for one another.

Show all related products (59 more) Hide additional products

Same therapeutic group 59

Professional reference for veterinary professionals. Not advertising and not a substitute for the product label/SPC.

For veterinary professionals only. It does not replace clinical judgement or the product label; check the dose in the official label (SPC). vetman is not liable for harm caused by using this information.

Trademarks belong to their owners; vetman is not affiliated with the manufacturers and receives no payment from them.

The database is protected under Chapter VII of the Law of Georgia on Copyright and Related Rights; automated or bulk copying is prohibited.

This reference is still growing. Missing a product? Let us know. · Report an error or request an addition · Updated: 23 Oct 2026

All of this shows in vetman as you prescribe

The dose for the patient's weight, registration in Georgia and controlled status, right on the prescription.

Register Demo ↗